Safety of current antiviral drugs for chronic hepatitis B
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2022.2045271
Abstract: ABSTRACT Introduction Oral nucleos(t)ide analogues (NUCs) are recommended as first-line therapy for chronic hepatitis B (CHB) due to higher HBV-DNA suppression rates and safety profile. Long-term treatment with NUCs is often necessary to achieve durable… read more here.
Keywords: long term; safety; chronic hepatitis; safety current ... See more keywords